Drug Search Results
More Filters [+]

LPCN-1021

Alternative Names: lpcn-1021, lpcn1021, lpcn 1021, tlando
Latest Update: 2024-06-25
Latest Update Note: News Article

Product Description

LPCN 1021, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. (Sourced from: https://ir.lipocine.com/Lipocine-Resubmits-NDA-for-Its-Oral-Testosterone-Product-Candidate-LPCN-1021-for-Treatment-of-Hypogonadism)

Mechanisms of Action: AR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lipocine
Company Location: SALT LAKE CITY X1 84108
Company CEO: Mahesh V. Patel
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LPCN-1021

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hypogonadism|Eunuchism

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LPCN 1021-18-001

P3

Completed

Eunuchism|Hypogonadism

2019-02-19

DF

P3

Completed

Hypogonadism|Eunuchism

2017-05-01

DV

P3

Completed

Hypogonadism|Eunuchism

2017-03-01

SOAR

P3

Completed

Eunuchism|Hypogonadism

2015-05-01

Recent News Events